Keck Medicine of USC opens new cancer treatment and imaging clinic in Newport Beach
Keck Medicine of USC expanded their presence in Orange County with the opening of a new cancer treatment and imaging center in Newport Beach, which they celebrated with an open house on Thursday, May 8.
The new state-of-the-art facility is located in a 12,500-square-foot space at 4590 MacArthur Blvd., near John Wayne Airport. That's just 15 minutes away from USC Norris' oncology locations in Newport Beach and Irvine, which means patients at those sites may no longer have to drive an hour north to get treatment.
'Our commitment is to bring world class, specialized, academic medicine to your patients without them having to brave the 5 Freeway all the way to Los Angeles,' said Rod Hanners, chief executive of Keck Medicine of USC. 'Our new, beautiful space is designed to create a relaxing, serene environment to help patients feel at ease while facing one of the biggest challenges of their lives.'
The facility on MacArthur is the first radiation treatment site in Orange County equipped to offer SCINTIX, a new form of therapy designated as a 'breakthrough' method of care for lung and bone cancer by the Food and Drug Administration. The new clinic had welcomed the first patient to undergo the treatment on Wednesday.
SCINTIX uses radioactive dyes to highlight cancer cells, providing up to the minute updates about their location in a patient's body. That allows proprietary equipment to precisely target tumors with radiation while minimizing harm to healthy cells.
'Keck's new location in Newport Beach is impressive,' said Marcia Manker, MemorialCare Orange Coast Medical Center chief executive. 'This new center offers the (SCINTIX) ReflexXion X1 technology, giving patients with lung or bone metastases a better prognosis.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 days ago
- Yahoo
NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs
USC brain tumor authority to accelerate four clinical trials including lead asset NEO100 nearing Phase 2a completion ahead of schedule Appointment bolsters FDA approval path while company explores AI and quantum computing to enhance drug delivery platform CALABASAS, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced the appointment of Josh Neman, PhD as its new Chief Clinical Officer (CCO). Dr. Neman brings with him a distinguished career at the intersection of cancer neuroscience, translational research, and academic medicine. Dr. Neman joins NeOnc Technologies Holdings Inc. (NeOnc) from the Keck School of Medicine at the University of Southern California (USC), where he serves as Associate Professor of Neurological Surgery and Physiology & Neuroscience, and Scientific Director of the USC Brain Tumor Center. At USC, he also leads the Cancer Biology and Genomics PhD Program and serves as Director of Cancer Research Training and Education Coordination at the USC Norris Comprehensive Cancer Center- a leading National Cancer Institute-designated cancer research hospital. A nationally recognized leader in neurooncological sciences and cancer neuroscience, Dr. Neman's research has advanced the understanding of how brain microenvironments influence the progression of brain tumors and metastases. His pioneering studies on tumor-neuron interactions, GABAergic signaling in cancer, and mechanisms of leptomeningeal dissemination have helped shape new therapeutic paradigms for both adult and pediatric brain tumors. 'I am deeply honored to join NeOnc at this exciting time,' said Dr. Neman. 'NeOnc's commitment to developing innovative therapeutics, including Blood Brain Barrier-penetrant compounds like NEO212 and NEO100, aligns perfectly with my lifelong passion to improve outcomes for patients with brain tumors. I look forward to helping lead the translation of promising discoveries from the lab into meaningful clinical impact.' In his role as Chief Clinical Officer, Dr. Neman will lead NeOnc's clinical development strategy, including investigator-initiated trials and precision oncology partnerships. He will also play a key role in expanding NeOnc's research collaborations with academic institutions, regulatory agencies, and patient advocacy groups. 'Dr. Neman's appointment signals a major step forward in NeOnc's mission to transform the treatment landscape for patients with life-threatening cancers with poor outcomes,' said Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies Holdings, Inc. 'His academic and clinical leadership, coupled with his deep expertise in brain tumor biology, will be instrumental in accelerating all four of our clinical trials—especially our lead asset, NEO100, which is approaching the completion of its Phase 2a trial with full enrollment achieved ahead of schedule. As we look to add AI and quantum computing into our expanding platform in drug delivery and bio-conjugation, Dr. Neman's appointment further strengthens our commitment to advancing precision therapies and driving toward FDA approval.' About NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI): NeOnc Technologies is a publicly traded, clinical-stage biopharmaceutical company developing innovative therapies for brain and central nervous system cancers. Its lead programs—NEO100-01, NEO100-02, NEO100-03, and NEO212—utilize proprietary formulations to bypass the blood-brain barrier and target malignancies with precision. The company's IP portfolio includes 176 patents worldwide, reflecting a broad platform with strong commercialization potential. For more about NeOnc and its pioneering technology, visit Important Cautions Regarding Forward-Looking Statements All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Generally, such forward-looking statements include statements regarding expectations, possible or assumed future actions, business strategies, events or results of operations, including statements regarding expectations or predictions or future financial or business performance or conditions and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate," or similar expressions. The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions. Actual results could differ materially from current projections or implied results. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management are under no obligation, and expressly disclaim any obligation, to update, alter or otherwise revise any forward-looking statements following the date of this news release, whether because of new information, future events or otherwise, except as required by law. 'NEO100' is a registered trademark of NeOnc Technologies Holdings, Inc. Company Contact:23975 Sorrento Park Suite 205, Calabasas, CA, 91302info@ Investor Relations:James CarbonaraHayden IR369 Lexington AvenueSecond FloorNew York, NY 10017Office: (646)-755-7412James@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Yahoo
Chronic Absenteeism Hasn't Gone Away After Lockdowns. Research Shows Poor Kids Are Hurt Most.
Chronic absenteeism has long been cited as one of the most severe lasting impacts of COVID-era school shutdowns. New research indicates that the problem is sticking around for groups of students already facing significant disadvantages. "The income gap really was the main driver that showed up over and over again," said University of Southern California (USC) education professor Morgan Polikoff during a presentation of his research at an American Enterprise Institute (AEI) event last week. "The fact that student-level income is the main driver here seems to be really important." Chronic absenteeism—often defined as when a student is absent for more than 10 percent of the school year—skyrocketed during the pandemic. According to AEI's absenteeism tracker, by 2022, national chronic absenteeism increased by 89 percent when compared to three years prior. While absenteeism has declined from its 2022 peak in most states that report such data, 2024 figures show it remains higher than pre-pandemic levels. Absolute rates of absenteeism varied broadly state by state. In Alabama, students had the lowest rate, peaking at 18 percent in 2022 and falling to 15 percent in 2024. By contrast, nearly half of all students in Washington, D.C., were chronically absent in 2022, dropping to a still-staggering 40 percent in 2024. According to Polikoff's research, low-income students in particular are facing persistent increases in absenteeism when compared to pre-pandemic numbers. Polikoff looked at school absenteeism data from North Carolina and Virginia. He explained that, when comparing absenteeism from before and after the pandemic, the attendance gap between low-income and non-low-income students grew dramatically. Post-pandemic, Virginia low-income students were 12.1 percentage points more likely to be chronically absent than other students, and in North Carolina, these students were 14.4 percentage points more likely to be chronically absent. Polikoff noted that the gap between different racial groups was relatively minor after controlling for income. "When looking in absolute terms, the most disadvantaged groups are typically more likely to have seen larger increases in chronic absenteeism," he said. "Racial gaps are not overly large, controlling for income and other things. How exactly to reverse these trends has long puzzled education professionals. School districts have tried everything from home visits to free ice cream and gift cards, yet the problem remains persistent. "[Absenteeism is] what the corona did," a 21-year-old told ProPublica reporter Alec MacGillis in a story co-published with The New Yorker last year. "They're sending the kids back to school, and they don't want to no more. They want to stay home and play on their computers." The post Chronic Absenteeism Hasn't Gone Away After Lockdowns. Research Shows Poor Kids Are Hurt Most. appeared first on
Los Angeles Times
6 days ago
- Los Angeles Times
USC and UCLA Team Up for World's First-in-Human Bladder Transplant
Historic surgery, the result of years of research at Keck Medicine of USC and UCLA Health, opens the door for improved treatment of non-functioning bladders Surgeons from Keck Medicine of USC and UCLA Health have performed the world's first-in-human bladder transplant. The surgery was successfully completed at Ronald Reagan UCLA Medical Center earlier this month in a joint effort by Inderbir Gill, MD, founding executive director of USC Urology, and Nima Nassiri, MD, urologic transplant surgeon and director of the UCLA Vascularized Composite Bladder Allograft Transplant Program. 'This surgery is a historic moment in medicine and stands to impact how we manage carefully selected patients with highly symptomatic 'terminal' bladders that are no longer functioning,' said Gill, who is also chair and Distinguished Professor of Urology and Shirley and Donald Skinner Chair in Urologic Cancer Surgery with the Keck School of Medicine of USC. 'Transplantation is a life-saving and life-enhancing treatment option for many conditions affecting major organs, and now the bladder can be added to the list.' 'This first attempt at bladder transplantation has been over four years in the making,' Nassiri said. 'For the appropriately selected patient, it is exciting to be able to offer a new potential option.' Nassiri, formerly a urology resident with the Keck School and now assistant professor of urology and kidney transplantation at UCLA, and Gill worked together for several years at the Keck School to develop the new surgical technique, design a clinical trial and secure the necessary regulatory approvals. Numerous pre-clinical procedures were performed both at Keck Medical Center of USC and OneLegacy, Southern California's organ procurement organization, to prepare for this first-in-human bladder transplant. The patient had been dialysis-dependent for seven years. He lost the majority of his bladder during surgery to resect cancer over five years ago, leaving the remainder of his bladder too small and compromised to function appropriately. Both of his kidneys were subsequently removed due to renal cancer. To address these deficits, Drs. Gill and Nassiri performed a combined kidney and bladder transplant, allowing the patient to immediately stop dialysis and produce urine for the first time in seven years. First, the kidney and then the bladder were transplanted. The new kidney was then connected to the new bladder. The entire procedure took approximately eight hours. 'The kidney immediately made a large volume of urine, and the patient's kidney function improved immediately,' Nassiri added. 'There was no need for any dialysis after surgery, and the urine drained properly into the new bladder.' 'Despite the complexity of the case, everything went according to plan and the surgery was successful,' said Gill. 'The patient is doing well, and we are satisfied with his clinical progress to date.' The recovery of the kidney and bladder from the donor was performed at OneLegacy's Transplant Recovery Center in Azusa, California. All parts of the procedure, including surgery and post-surgical monitoring during the transplantation, were aligned with the highest current clinical and research standards. Millions of people around the globe experience some degree of bladder disease and dysfunction. Some develop terminal bladders that are either non-functioning and/or cause constant pain, repeated infections and other complications. Current treatment for severe terminal cases of bladder dysfunction or a bladder that has been removed due to various conditions includes replacement or augmentation of the urinary reservoir. These surgeries use a portion of a patient's intestine to create a new bladder or a pathway for the urine to exit the body. 'While these surgeries can be effective, they come with many short- and long-term risks that compromise a patient's health, such as recurrent infections, compromised kidney function and digestive issues,' said Gill. 'A bladder transplant, on the other hand, delivers a more 'normal' urinary reservoir and may circumvent some of the challenges associated with using the intestine,' said Nassiri. The biggest risks of organ transplant are the body's potential rejection of the organ and side effects caused by the mandatory immunosuppressive drugs given to prevent organ rejection. 'Because of the need for long-term immunosuppression, the best current candidates are those with a pre-existing organ transplant or those who need a combined kidney and bladder transplant,' said Nassiri. As a first-in-human attempt, there are naturally many unknowns associated with the procedure, such as how well the transplanted bladder will function immediately and over time, and how much immunosuppression will ultimately be needed. 'Despite the unknowns, our goal is to understand if bladder transplantation can help patients with severely compromised bladders lead healthier lives,' said Gill. Bladder transplants have not been done previously, in part because of the complicated vascular structure of the pelvic area and the technical complexity of the procedure. As part of the research and development stage, Gill and Nassiri successfully completed numerous practice transplantation surgeries at Keck Medical Center of USC, including the first-ever robotic bladder retrievals and successful robotic transplantations in five recently deceased donors with cardiac function maintained on ventilator support. Several non-robotic trial runs of bladder recovery were performed at OneLegacy by Gill and Nassiri, allowing them to perfect the technique while working alongside multidisciplinary surgical teams. The bladder transplant was done as part of a UCLA clinical trial. Gill and Nassiri hope to perform more bladder transplants together in the near future. Under Gill's leadership, USC Urology has rapidly established itself as a pioneer and world leader in the most advanced robotic urologic oncologic surgeries for kidney, bladder, prostate, testicular and penile cancers and has achieved important milestones leveraging machine learning and artificial intelligence to optimize patient outcomes. Information was sourced from Keck Medicine of USC. To learn more, contact
